RESMED INC(RMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #50 of 2,879 stocksTOP 5%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
RMD Stock Analysis & AI Quality Score
AI stock analysis and institutional research for RESMED INC (RMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RMD at 79.8/100 on a 32-signal composite quality model, placing it at rank #50 of 2,879 stocks — the top 5% of the AI-ranked universe. RMD scores in the top quartile across balance sheet strength (96.0), profitability (90.4), free cash flow (87.6). Shareholder dilution risk is elevated at 43.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), RESMED INC reports quarterly revenue of $1.4B, net income of $398.7M, an operating margin of 34.9%. Top institutional holders of RMD by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. RMD trades on the NYSE exchange and files with the SEC under CIK 943819. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RESMED INC directly from SEC EDGAR. RESMED INC's 13F Pro composite quality score has ranged between 8 and 84 since 2021, currently 79.8 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q3 2026
$1.4B
Net Income
Q3 2026
$398.7M
Free Cash Flow
Q3 2026
$520.5M
Operating Margin
Q3 2026
34.9%
D/E Ratio
Q3 2026
0.10
Get alerted when RMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for RESMED INC including:
Top Institutional Holders of RMD
BlackRock, Inc.
$2.7B12,094,023 shVANGUARD CAPITAL MANAGEMENT LLC
$2.1B9,466,416 shVANGUARD PORTFOLIO MANAGEMENT LLC
$1.8B7,863,922 shSTATE STREET CORP
$1.5B6,643,168 shBank of New York Mellon Corp
$1.1B4,925,386 shGEODE CAPITAL MANAGEMENT, LLC
$973.8M4,352,873 shMORGAN STANLEY
$603.1M2,686,821 shInvesco Ltd.
$439.2M1,956,614 shNORTHERN TRUST CORP
$387.4M1,725,693 shFIRST TRUST ADVISORS LP
$345.2M1,537,825 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $2.7B | 12,094,023 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.1B | 9,466,416 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.8B | 7,863,922 |
| STATE STREET CORP | $1.5B | 6,643,168 |
| Bank of New York Mellon Corp | $1.1B | 4,925,386 |
| GEODE CAPITAL MANAGEMENT, LLC | $973.8M | 4,352,873 |
| MORGAN STANLEY | $603.1M | 2,686,821 |
| Invesco Ltd. | $439.2M | 1,956,614 |
| NORTHERN TRUST CORP | $387.4M | 1,725,693 |
| FIRST TRUST ADVISORS LP | $345.2M | 1,537,825 |
More Healthcare Companies
View all Healthcare →Put RMD on your watchlist
Track score changes the day RESMED INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RMD a good stock to buy?
13F Pro's AI-powered analysis of RESMED INC (RMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RMD are available on the RMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own RMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RESMED INC's investment landscape.